Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Prostate Cancer

Free Subscription 13.05.2019 4 BJU Int 1 BMC Cancer 3 BMC Urol 1 Br J Cancer 1 Cancer 2 Cancer Res 1 Eur Radiol 5 Eur Urol 1 Hum Pathol 1 Int J Cancer 1 Int J Urol 1 J Magn Reson Imaging 1 J Nucl Med 12 J Urol 2 JAMA 1 Oncology 1 PLoS One 1 Proc Natl Acad Sci U S A 1 Urol Int 3 Urology

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

BJU Int

1. DEL RE M, Crucitta S, Sbrana A, Rofi E, et al
   AR-V7 and AR-FL expression is associated with clinical outcome: a translational study in patients with castrate resistant prostate cancer.
   BJU Int. 2019 May 4. doi: 10.1111/bju.14792.
   PubMed     Text format     Abstract available
   
   
2. FINE ND, LaPolla F, Epstein M, Loeb S, et al
   Genomic Classifiers for Treatment Selection in Newly Diagnosed Prostate Cancer.
   BJU Int. 2019 May 4. doi: 10.1111/bju.14799.
   PubMed     Text format     Abstract available
   
   
3. REMMERS S, Verbeek JFM, Nieboer D, van der Kwast T, et al
   Predicting biochemical recurrence and prostate cancer specific mortality after radical prostatectomy: comparison of six prediction models in a cohort of screen and clinically detected prostate cancer patients.
   BJU Int. 2019 May 4. doi: 10.1111/bju.14790.
   PubMed     Text format     Abstract available
   
   
4. GNANAPRAGASAM VJ, Barrett T, Thankapannair V, Thurtle D, et al
   Using prognosis to guide inclusion criteria, define standardized end-points and stratify follow up in active surveillance for prostate cancer.
   BJU Int. 2019 May 7. doi: 10.1111/bju.14800.
   PubMed     Text format     Abstract available
   
   

   
   BMC Cancer

5. GEORGESCU C, Corbin JM, Thibivilliers S, Webb ZD, et al
   A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
   BMC Cancer. 2019;19:423.
   PubMed     Text format     Abstract available
   
   

   
   BMC Urol

6. KIM IE JR, Kim S, Srivastava A, Saraiya B, et al
   Similar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer.
   BMC Urol. 2019;19:33.
   PubMed     Text format     Abstract available
   
   
7. YOON SE, Kim Y, Cho J, Kang M, et al
   A retrospective feasibility study of biweekly docetaxel in patients with high-risk metastatic castration-naive prostate cancer.
   BMC Urol. 2019;19:30.
   PubMed     Text format     Abstract available
   
   
8. KIM MS, Jang WS, Chung DY, Koh DH, et al
   Effect of prostate gland weight on the surgical and oncological outcomes of extraperitoneal robot-assisted radical prostatectomy.
   BMC Urol. 2019;19:1.
   PubMed     Text format     Abstract available
   
   

   
   Br J Cancer

9. MOUSTSEN IR, Larsen SB, Duun-Henriksen AK, Tjonneland A, et al
   Risk of cardiovascular events in men treated for prostate cancer compared with prostate cancer-free men.
   Br J Cancer. 2019 May 8. pii: 10.1038/s41416-019-0468.
   PubMed     Text format     Abstract available
   
   

   
   Cancer

10. PINSKY PF, Black A, Daugherty SE, Hoover R, et al
    Metastatic prostate cancer at diagnosis and through progression in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
    Cancer. 2019 May 8. doi: 10.1002/cncr.32176.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Res

11. KAMINSKI L, Torrino S, Dufies M, Djabari Z, et al
    PGC-1alpha inhibits polyamine synthesis to suppress prostate cancer aggressiveness.
    Cancer Res. 2019 May 7. pii: 0008-5472.CAN-18-2043.
    PubMed     Text format     Abstract available
    
    
12. GORDON JA, Noble JW, Midha A, Derakhshan F, et al
    Upregulation of Scavenger receptor B1 is required for steroidogenic and non-steroidogenic cholesterol metabolism in prostate cancer.
    Cancer Res. 2019 May 7. pii: 0008-5472.CAN-18-2529.
    PubMed     Text format     Abstract available
    
    

    
    Eur Radiol

13. BONEKAMP D, Schelb P, Wiesenfarth M, Kuder TA, et al
    Histopathological to multiparametric MRI spatial mapping of extended systematic sextant and MR/TRUS-fusion-targeted biopsy of the prostate.
    Eur Radiol. 2019;29:1820-1830.
    PubMed     Text format     Abstract available
    
    

    
    Eur Urol

14. SUARDI N
    Re: Active Surveillance of Prostate Cancer is a Viable Option in Men Younger than 60 Years.
    Eur Urol. 2019 May 2. pii: S0302-2838(19)30341.
    PubMed     Text format    
    
    
15. MARGEL D, Ber Y, Baniel J
    Re: Optimizing Patient's Selection for Prostate Biopsy: A Single Institution Experience with Multi-parametric MRI and the 4Kscore Test for the Detection of Aggressive Prostate Cancer.
    Eur Urol. 2019 May 2. pii: S0302-2838(19)30338.
    PubMed     Text format    
    
    
16. LOEB S
    Overactive Surveillance: Is "Conservative" Management for Low-risk Prostate Cancer Too Aggressive?
    Eur Urol. 2019 May 3. pii: S0302-2838(19)30282.
    PubMed     Text format    
    
    
17. SIERRA PS
    Re: Felix Preisser, Felix K.H. Chun, Raisa S. Pompe, et al. Persistent Prostate-specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.01.048: Useful Prognostic Info
    Eur Urol. 2019 May 4. pii: S0302-2838(19)30355.
    PubMed     Text format    
    
    
18. DONNELLY DW, Gavin A, Downing A, Hounsome L, et al
    Regional Variations in Quality of Survival Among Men with Prostate Cancer Across the United Kingdom.
    Eur Urol. 2019 May 3. pii: S0302-2838(19)30329.
    PubMed     Text format     Abstract available
    
    

    
    Hum Pathol

19. SEHGAL PD, Bauman TM, Nicholson TM, Vellky JE, et al
    Tissue-specific quantification and localization of androgen and estrogen receptors in prostate Cancer.
    Hum Pathol. 2019 May 2. pii: S0046-8177(19)30074.
    PubMed     Text format     Abstract available
    
    

    
    Int J Cancer

20. BRADBURY KE, Appleby PN, Tipper SJ, Travis RC, et al
    Circulating insulin-like growth factor I in relation to melanoma risk in the European Prospective Investigation into Cancer and Nutrition.
    Int J Cancer. 2018 Sep 7. doi: 10.1002/ijc.31854.
    PubMed     Text format     Abstract available
    
    

    
    Int J Urol

21. TANAKA N, Nishimura K, Okajima E, Ina K, et al
    Docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration for castration-resistant prostate cancer: Long-term outcomes.
    Int J Urol. 2019 May 5. doi: 10.1111/iju.14009.
    PubMed     Text format     Abstract available
    
    

    
    J Magn Reson Imaging

22. MA S, Xie H, Wang H, Han C, et al
    MRI-Based Radiomics Signature for the Preoperative Prediction of Extracapsular Extension of Prostate Cancer.
    J Magn Reson Imaging. 2019 May 6. doi: 10.1002/jmri.26777.
    PubMed     Text format     Abstract available
    
    

    
    J Nucl Med

23. CARRASQUILLO JA, Fine B, Pandit-Taskar N, Larson SM, et al
    Imaging metastatic castration-resistant prostate cancer patients with (89)Zr-DFO-MSTP2109A anti-STEAP1 antibody.
    J Nucl Med. 2019 May 3. pii: jnumed.118.222844. doi: 10.2967/jnumed.118.222844.
    PubMed     Text format     Abstract available
    
    

    
    J Urol

24. DASKIVICH TJ
    Editorial Comment.
    J Urol. 2019;201:733.
    PubMed     Text format    
    
    
25. KEEGAN KA
    Editorial Comment.
    J Urol. 2019;201:749.
    PubMed     Text format    
    
    
26. GRUBB R
    Editorial Comment.
    J Urol. 2019;201:740-741.
    PubMed     Text format    
    
    
27. SAMMON J
    Editorial Comment.
    J Urol. 2019;201:733-734.
    PubMed     Text format    
    
    
28. TANEJA SS
    Re: A 17-Gene Panel for Prediction of Adverse Prostate Cancer Pathologic Features: Prospective Clinical Validation and Utility.
    J Urol. 2019 May 7:10109701JU0000559603179075.
    PubMed     Text format    
    
    
29. ATALA A
    Re: Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories.
    J Urol. 2019 May 7:101097JU0000000000000330. doi: 10.1097/JU.0000000000000330.
    PubMed     Text format    
    
    
30. ATALA A
    Re: Inhibition of De Novo Lipogenesis Targets Androgen Receptor Signaling in Castration-Resistant Prostate Cancer.
    J Urol. 2019 May 7:10109701JU0000559616036260.
    PubMed     Text format    
    
    
31. GONTERO P, Marra G, Alessio P, Filippini C, et al
    Salvage radical prostatectomy for recurrent prostate cancer: morbidity and functional outcomes from a large multicenter series of open versus robotic approaches.
    J Urol. 2019 May 10:101097JU0000000000000327. doi: 10.1097/JU.0000000000000327.
    PubMed     Text format     Abstract available
    
    
32. GRIEBLING TL
    Re: Systematic Review and Network Meta-Analysis on the Relative Efficacy of Osteoporotic Medications: Men with Prostate Cancer on Continuous Androgen-Deprivation Therapy to Reduce Risk of Fragility Fractures.
    J Urol. 2019 May 10:10109701JU000055973645783.
    PubMed     Text format    
    
    
33. TOM MC, Nguyen JK, Luciano R, Mian OY, et al
    Impact of Cribriform Pattern and Intraductal Carcinoma on Gleason 7 Prostate Cancer Treated with External Beam Radiotherapy.
    J Urol. 2019 May 6:101097JU0000000000000316. doi: 10.1097/JU.0000000000000316.
    PubMed     Text format     Abstract available
    
    
34. HARPER BT, Dykes TE, Terris MK
    Editorial Comment.
    J Urol. 2019;201:749.
    PubMed     Text format    
    
    
35. TANEJA SS
    Re: Radical Prostatectomy or Watchful Waiting in Prostate Cancer-29-Year Follow-up.
    J Urol. 2019 May 7:101097JU0000000000000323. doi: 10.1097/JU.0000000000000323.
    PubMed     Text format    
    
    

    
    JAMA

36. EHDAIE B, Carlsson S, Vickers A
    Racial Disparities in Low-Risk Prostate Cancer.
    JAMA. 2019;321:1726-1727.
    PubMed     Text format    
    
    
37. MAHAL BA, Huang FW
    Racial Disparities in Low-Risk Prostate Cancer-Reply.
    JAMA. 2019;321:1727-1728.
    PubMed     Text format    
    
    

    
    Oncology

38. GLYBOCHKO PV, Amosov AV, Krupinov GE, Petrovskii NV, et al
    Hemiablation of Localized Prostate Cancer by High-Intensity Focused Ultrasound: A Series of 35 Cases.
    Oncology. 2019 May 9:1-5. doi: 10.1159/000499739.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

39. STRANDBERG S, Hashemi A, Axelsson J, Riklund K, et al
    Optimization of PET reconstruction algorithm, SUV thresholding algorithm and PET acquisition time in clinical 11C-acetate PET/CT.
    PLoS One. 2018;13:e0209169.
    PubMed     Text format     Abstract available
    
    

    
    Proc Natl Acad Sci U S A

40. ABIDA W, Cyrta J, Heller G, Prandi D, et al
    Genomic correlates of clinical outcome in advanced prostate cancer.
    Proc Natl Acad Sci U S A. 2019 May 6. pii: 1902651116.
    PubMed     Text format     Abstract available
    
    

    
    Urol Int

41. PORCARO AB, Cacciamani GE, Sebben M, Tafuri A, et al
    Lymph Nodes Invasion of Marcille's Fossa Associates with High Metastatic Load in Prostate Cancer Patients Undergoing Extended Pelvic Lymph Node Dissection: The Role of "Marcillectomy".
    Urol Int. 2019 May 8:1-8. doi: 10.1159/000500330.
    PubMed     Text format     Abstract available
    
    

    
    Urology

42. HAAHR MK, Jensen CH, Toyserkani NM, Andersen DC, et al
    A 12-Month Follow-up After a Single Intracavernous Injection of Autologous Adipose-derived Regenerative Cells in Patients with Erectile Dysfunction Following Radical Prostatectomy: An Open-label Phase I Clinical Trial.
    Urology. 2018 Jun 27. pii: S0090-4295(18)30586.
    PubMed     Text format     Abstract available
    
    
43. MODI PK
    EDITORIAL COMMENT.
    Urology. 2019;124:105-106.
    PubMed     Text format    
    
    
44. DRAULANS C, Everaerts W, Isebaert S, Gevaert T, et al
    Impact of MRI on prostate cancer staging and EAU risk classification.
    Urology. 2019 Apr 30. pii: S0090-4295(19)30386.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: